FIG URE 1 Exponential decay in Lyso-Gb1 plasma levels following ERT. Lyso-Gb1 levels were normalized based on the pre-ERT level for each patient and an exponential curve (red line) was fitted to the pooled data. 
Glucosylsphingosine is a reliable response biomarker in Gaucher disease
To the Editor:
Gaucher disease (GD) is an autosomal recessive lysosomal disorder caused by impaired activity of b-glucocerebrosidase due to mutations in the GBA1 gene. While glucosylsphingosine (Lyso-Gb1), the deacylated form of glucosylceramide, is an optimal diagnostic biomarker of GD, 1, 2 there is a substantial lack of studies identifying a valid biomarker which quantifies patient response to therapy (rate or response biomarker). Difficulties in identifying rate biomarkers in patients with GD are due to its diverse natural history and wide variability in patient response to therapy.
Since any disease parameter that changes with therapy potentially can serve as rate biomarker, we assessed the value of key disease parameters such as biomarkers by retrospectively analyzed data that were obtained from a homogenous population of patients. This cohort of GD patients, all non-splenectomized GD, homozygote to the nonneuronopathic N370S (c.1226A>G) mutation in the GBA1 gene and who received a low dose of enzyme replacement therapy (ERT, 15 units per kg per month), partially enabled us to overcome response variability and to assess the value of potential rate biomarkers more reliably. This study was approved by the ethics committee of Shaare Zedek Medical Center (0165-17-SZMC). See Supporting Information for detailed methods.
We longitudinally assessed the effect of ERT on key disease parameters in 25 GD patients (Supporting Information Table) . Parameters included Lyso-Gb1 levels, platelet counts, hemoglobin values, and the normalized volumes of the spleen and liver (multiples of norms).
Seventeen patients received an ERT of velaglucerase alfa (VPRIV®, Shire), four received imiglucerase (Cerezyme®, Genzyme), and an additional four received taliglucerase alfa (Elelyso®, Pfizer). One patient (female, treated with imiglucerase) was excluded from liver and spleen volume analyses as her pre-treatment measures were lacking.
Following ERT, Lyso-Gb1 levels decreased (25 patients; average: We also assessed the feasibility of using the calculated half-time of decay for Lyso-Gb1 as a biomarker for spleen normalization with different ERTs. For this purpose, we analyzed data from patients who received velaglucerase alfa (17 patients) separately from data of those who received imiglucerase or taliglucerase alfa (7 patients). The calculated half-life of Lyso-Gb1 in the velaglucerase alfa group was 14.8 months (95% interval: 13.2-16.9 months) and for the imiglucerase/taliglucerase alfa group was 17.6 months (95% interval: 13.9-24.1 months). Analysis of spleen volume normalization showed that it followed the same pattern. In patients on velaglucerase alfa the calculated decay half-life for spleen shrinking was 118 months (95% interval: 90-172 months), notably shorter than the value calculated for patients receiving imiglucerase/taliglucerase alfa treatments (138 months, 95%
interval of 92-275 months).
Elevated Lyso-Gb1 levels in GD patients have been previously reported, 1,2 and was shown to be superior diagnostic biomarker for the disease when compared to chitotriosidase and CCL18. 1, 2 This lipid is considered a contributing factor to the pathophysiology of the disease. [3] [4] [5] The current retrospective study demonstrates that LysoGb1 is also valuable as a rate biomarker (type I or pharmacological bio-
). Rate biomarkers allow monitoring patient response to ERT, predicting treatment outcome and comparing efficacy among different
ERTs and between ERTs and other therapeutic modalities.
Decrease in Lyso-Gb1 levels following ERT in GD patients was shown in previous studies. 1,2 However, these studies included patients with wide variation in GBA1 mutation types, patients with and without spleen, different modes of therapy (ERT and substance reduction therapy), and variable dose of ERT. In addition, these studies did not measure the utility of Lyso-Gb1 as a rate biomarker and did not compare it to other disease parameters which are commonly employed as such.
Hence it has remained difficult to demonstrate the precise pattern of decay of this substance. Our study addresses this caveat.
We conclude that Lyso-Gb1, which is presently the most specific and sensitive diagnostic biomarker of GD, is also the most reliable rate biomarker. In addition it has the potential to promote resolution of persisting issues in the treatment of GD such as the optimal dose of ERT, the need to shorten the duration of clinical trials, and predicting longterm organ response to therapy. 
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Heterogeneous hemoglobin lower thresholds in clinical laboratories
Accurate and harmonized definitions of anemia are critical for clinical management of patients and for ascertaining the epidemiology of the problem in public health. We surveyed laboratories participating in the UK External Quality Assurance programme (The UK NEQAS, a charitable consortium of external quality assessment laboratories), to determine the thresholds they used to define anemia. We found that while most laboratories provide sex-specific thresholds, few laboratories used distinct thresholds in pregnancy, children, postmenopausal women, or elderly people. Lower thresholds (often used clinically to define anemia) varied markedly between laboratories, especially among women, children and in pregnancy. Most laboratories cited textbook sources for their thresholds; the thresholds used were often discordant with that cited in the reference. The evidence underlying hemoglobin thresholds to define anemia remains limited, thus heterogeneity between laboratories is perhaps not unexpected.
Anemia is considered to exist when the hemoglobin concentra- E142 |
